Doc for nasal carriers of MRSA
**Core Concept**
The question is testing the use of decolonization therapy in the management of nasal carriers of Methicillin-Resistant Staphylococcus Aureus (MRSA). Decolonization aims to reduce or eliminate the carriage of MRSA in individuals, thereby preventing transmission and infection.
**Why the Correct Answer is Right**
The correct answer is based on the use of topical antimicrobial agents, specifically muiprocin, which is a potent inhibitor of bacterial protein synthesis. Muiprocin is applied topically to the anterior nares to reduce or eliminate MRSA colonization. The mechanism of action involves the inhibition of isoleucyl-tRNA synthetase, an essential enzyme for bacterial protein synthesis.
**Why Each Wrong Option is Incorrect**
**Option A:** Chlorhexidine is an antiseptic commonly used for skin preparation and hand hygiene. While it has antimicrobial properties, it is not the preferred agent for decolonization of MRSA nasal carriers.
**Option B:** Cephalosporins are a class of beta-lactam antibiotics that are effective against a wide range of bacterial infections. However, they are not typically used for decolonization of MRSA nasal carriers due to the risk of promoting antibiotic resistance.
**Option C:** Vancomycin is a glycopeptide antibiotic that is effective against MRSA. However, it is not typically used for decolonization of MRSA nasal carriers due to its potential for systemic absorption and toxicity.
**Clinical Pearl / High-Yield Fact**
Muiprocin resistance is a concern in the management of MRSA decolonization. Resistance rates can be as high as 20-30% in some populations, highlighting the need for regular surveillance and alternative decolonization strategies.
**Correct Answer: D. Muiprocin**